Publication Name	World Journal of Gastroenterology
Manuscript ID	28246
Country	Japan

Received	2016-06-29 15:18
Peer-Review Started	2016-06-29 15:28
First Decision by Editorial Office Director
Return for Revision	2016-08-23 10:14
Revised	2016-09-06 15:46
Publication Fee Transferred
Second Decision by Editor	2016-09-21 15:47
Second Decision by Editor-in-Chief	2016-09-22 17:04
Final Decision by Editorial Office Director	2016-09-28 17:51
Articles in Press	2016-09-28 17:51
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-10-17 20:16
Publish the Manuscript Online	2016-10-26 17:34

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Clinical Trials Study
Article Title	Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Issei Saeki, Naoki Yamamoto, Takahiro Yamasaki, Taro Takami, Masaki Maeda, Koichi Fujisawa, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Koichi Uchida, Kenji Tani and Isao Sakaida
Funding Agency and Grant Number	Funding Agency Grant Number Grants-in-Aid for Scientific Research from the Japan Society for the Program of Science 23590978 Grants-in-Aid for Scientific Research from the Japan Society for the Program of Science 16H05287 Strategic Research Promotion Program from Yamaguchi University
Corresponding Author	Takahiro Yamasaki, MD, PhD, Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami Kogushi, Ube, Yamaguchi 755-8505, Japan. t.yama@yamaguchi-u.ac.jp
Key Words	Liver tumor; Hepatocellular carcinoma; Advanced stage; Iron-chelator; Deferasirox
Core Tip	There are currently no established second-line chemotherapies for advanced hepatocellular carcinoma (HCC) patients. Iron chelators exert antiproliferative effects in several cancers. We demonstrated the inhibition of HCC by deferasirox (DFX) in the basic study. However, the efficacy of DFX in our clinical study could not be verified due to dose-limiting toxicities. Although iron chelators have promising therapeutic potential, further examinations are necessary to establish their clinical applications.
Publish Date	2016-10-26 17:34
Citation	Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977
URL	http://www.wjgnet.com/1007-9327/full/v22/i40/8967.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i40.8967

Full Article (PDF)	WJG-22-8967.pdf
Full Article (Word)	WJG-22-8967.doc